Persevere Therapeutics Started Ovarian Cancer Trial
The first patient was treated in a clinical trial for platinum-resistant ovarian cancer in Philadelphia.
Updated on Sept. 24, 2026 in Cancer
Persevere Therapeutics has treated the first patient in its MIROC-1 Phase 2a clinical trial. The study evaluates the efficacy of misetionamide as a monotherapy for patients diagnosed with platinum-resistant ovarian cancer.
Why it matters
The trial aims to address the needs of patients with platinum-resistant ovarian cancer by testing a treatment that targets MYC, a protein known to drive tumor growth and proliferation.
The MIROC-1 trial targets 18 patients across four U.S. cancer centers to test the inhibitor misetionamide. This follows national statistics showing approximately 21,000 annual ovarian cancer diagnoses and 12,400 deaths.
The players
Persevere Therapeutics
This is the pharmaceutical company sponsoring the development of misetionamide to treat ovarian cancer.
Abramson Cancer Center
Part of the University of Pennsylvania, this facility serves as one of the four clinical sites participating in the study.
The details
Administered as a monotherapy, the drug works by inhibiting MYC, which is responsible for tumor growth. The study is an open-label, single-arm Phase 2a trial that initially began at the Abramson Cancer Center of the University of Pennsylvania.
Timeline
September 24, 2026: The first patient was treated in the MIROC-1 trial.
September 2026: The clinical trial was initiated.
October 2026: Screening is expected to begin at two additional clinical sites.
The Big Picture
This research follows the MIROC-1 trial, representing a targeted approach to oncological intervention. The trial marks a shift toward specific protein inhibition as a primary strategy for treating platinum-resistant malignancies.
The trial provides a new experimental treatment pathway for patients who have not responded to platinum-based chemotherapy. While the study is currently limited to 18 participants, successful results could eventually lead to broader therapeutic options.
The takeaway
Clinical trials for rare or resistant cancer types offer critical data on emerging drug therapies. Patients should consult with their oncologists to understand if current clinical research trials may be suitable for their specific medical history.
Further reading
For additional context on research in this field, visit the Cancer section.
Source note: This article includes information reported by Firstwordpharma.
